Zhang J, Madge H, Mahmoud A, Lu L, Wang W, Huang W
NPJ Vaccines. 2025; 10(1):9.
PMID: 39809901
PMC: 11733015.
DOI: 10.1038/s41541-024-01050-4.
Lai C, Xie J, Lai M, Wu Z, Lin J, Huang Y
NPJ Vaccines. 2024; 9(1):46.
PMID: 38409165
PMC: 10897429.
DOI: 10.1038/s41541-024-00839-7.
Fulurija A, Cunningham M, Korotkova N, Masterson M, Bansal G, Baker M
BMJ Glob Health. 2024; 8(Suppl 9).
PMID: 38164699
PMC: 10729269.
DOI: 10.1136/bmjgh-2023-013534.
Wang J, Ma C, Li M, Gao X, Wu H, Dong W
Vaccines (Basel). 2023; 11(9).
PMID: 37766186
PMC: 10534548.
DOI: 10.3390/vaccines11091510.
Ozberk V, Zaman M, Lepletier A, Eskandari S, Kaden J, Mills J
Nat Commun. 2023; 14(1):5963.
PMID: 37749129
PMC: 10520070.
DOI: 10.1038/s41467-023-41410-7.
Streptolysin O Deficiency in Streptococcus pyogenes M1T1 Mutant Strain Attenuates Virulence in and Infection Models.
Langshaw E, Reynolds S, Ozberk V, Dooley J, Calcutt A, Zaman M
mBio. 2023; 14(1):e0348822.
PMID: 36744883
PMC: 9972915.
DOI: 10.1128/mbio.03488-22.
Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model.
Reynolds S, Mohamed Rafeek R, Hamlin A, Lepletier A, Pandey M, Ketheesan N
NPJ Vaccines. 2023; 8(1):9.
PMID: 36739443
PMC: 9899064.
DOI: 10.1038/s41541-023-00604-2.
Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.
Iyer V, Sagar V, Toor D, Lyngdoh V, Nongrum G, Kapoor M
Cureus. 2023; 14(12):e33146.
PMID: 36721580
PMC: 9884514.
DOI: 10.7759/cureus.33146.
The Role of Streptococcal Cell-Envelope Proteases in Bacterial Evasion of the Innate Immune System.
McKenna S, Huse K, Giblin S, Pearson M, Majid Al Shibar M, Sriskandan S
J Innate Immun. 2021; 14(2):69-88.
PMID: 34649250
PMC: 9082167.
DOI: 10.1159/000516956.
IL-33/ST2 Axis Plays a Protective Effect in Infection through Strengthening of the Innate Immunity.
Kuo C, Chen W, Yu H, Tsai Y, Chang Y, Chang C
Int J Mol Sci. 2021; 22(19).
PMID: 34638904
PMC: 8509005.
DOI: 10.3390/ijms221910566.
Utility of Human Immune Responses to GAS Antigens as a Diagnostic Indicator for ARF: A Systematic Review.
Salie M, Rampersadh K, Muhamed B, Engel K, Zuhlke L, Dale J
Front Cardiovasc Med. 2021; 8:691646.
PMID: 34355030
PMC: 8329041.
DOI: 10.3389/fcvm.2021.691646.
Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.
Pandey M, Ozberk V, Eskandari S, Shalash A, Joyce M, Saffran H
Clin Transl Immunology. 2021; 10(3):e1260.
PMID: 33732459
PMC: 7937407.
DOI: 10.1002/cti2.1260.
A multivalent T-antigen-based vaccine for Group A Streptococcus.
Loh J, Rivera-Hernandez T, McGregor R, Khemlani A, Tay M, Cork A
Sci Rep. 2021; 11(1):4353.
PMID: 33623073
PMC: 7902606.
DOI: 10.1038/s41598-021-83673-4.
Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from Mutant Streptococcus pyogenes.
Ozberk V, Reynolds S, Huo Y, Calcutt A, Eskandari S, Dooley J
mBio. 2021; 12(1).
PMID: 33622722
PMC: 8545125.
DOI: 10.1128/mBio.03537-20.
Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development.
Wang G, Zhao J, Zhao Y, Wang S, Feng S, Gu G
Vaccines (Basel). 2021; 9(2).
PMID: 33572233
PMC: 7915350.
DOI: 10.3390/vaccines9020139.
The role of vaccines in combatting antimicrobial resistance.
Micoli F, Bagnoli F, Rappuoli R, Serruto D
Nat Rev Microbiol. 2021; 19(5):287-302.
PMID: 33542518
PMC: 7861009.
DOI: 10.1038/s41579-020-00506-3.
Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.
Reynolds S, Pandey M, Dooley J, Calcutt A, Batzloff M, Ozberk V
Sci Rep. 2021; 11(1):127.
PMID: 33420258
PMC: 7794325.
DOI: 10.1038/s41598-020-80508-6.
M-protein based vaccine induces immunogenicity and protection from when delivered on a high-density microarray patch (HD-MAP).
Mills J, Jayashi Flores C, Reynolds S, Wun C, Calcutt A, Baker S
NPJ Vaccines. 2020; 5(1):74.
PMID: 32802413
PMC: 7414110.
DOI: 10.1038/s41541-020-00222-2.
Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191.
Sanduja P, Gupta M, Somani V, Yadav V, Dua M, Hanski E
Nat Commun. 2020; 11(1):3545.
PMID: 32669564
PMC: 7363907.
DOI: 10.1038/s41467-020-17299-x.
Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.
Herrera A, Van Hove C, Hanson M, Dale J, Tweten R, Huber V
PLoS One. 2020; 15(6):e0235139.
PMID: 32574205
PMC: 7310742.
DOI: 10.1371/journal.pone.0235139.